Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Gastroesophageal Adenocarcinoma
Interventions
DRUG

Paclitaxel

80 mg/m²

DRUG

Ramucirumab

8 mg/kg

DRUG

Zanidatamab

Dose and schedule to be assigned at enrollment

Trial Locations (18)

T2N 5G2

RECRUITING

Arthur J.E. Child Comprehensive Cancer Centre, Calgary

V5Z 4E6

RECRUITING

BCCA - Vancouver, Vancouver

R3E 0V9

RECRUITING

CancerCare Manitoba, Winnipeg

B3H 1V7

RECRUITING

QEII Health Sciences Centre, Halifax

L4M 6M2

RECRUITING

Royal Victoria Regional Health Centre, Barrie

L8V 5C2

RECRUITING

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 2V7

RECRUITING

Kingston Health Sciences Centre, Kingston

N2G 1G3

RECRUITING

Waterloo Regional Health Network (WRHN), Kitchener

N6A 5W9

RECRUITING

London Health Sciences Centre Research Inc., London

L1G 2B9

RECRUITING

Lakeridge Health Oshawa, Oshawa

K1H 8L6

RECRUITING

Ottawa Hospital Research Institute, Ottawa

M4N 3M5

RECRUITING

Odette Cancer Centre, Toronto

M5B 1W8

RECRUITING

St. Michael's Hospital, Toronto

M5G 2M9

RECRUITING

University Health Network, Toronto

H2X 3E4

RECRUITING

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal

H4J 1C5

RECRUITING

Centre Integre Universitaire De Sante Et De Services, Montreal

S4T 7T1

RECRUITING

Allan Blair Cancer Centre, Regina

S7N 4H4

RECRUITING

Saskatoon Cancer Centre, Saskatoon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK